EYLEA® 8mg Dosing

Flexible Dosing Options

Extend up to Q16 dosing directly after only 3 loading doses in both nAMD and DME with EYLEA® 8mg

Extend up to Q16 dosing directly after only 3 loading doses in both nAMD and DME with EYLEA 8mg

The frequency of monitoring visits should be based on the patient’s status and at the physician’s discretion.

Dosing diagram for illustrative purpose only.

After reaching Q16, patients can be extended to Q20 using an extension method such as T&E*

After reaching Q16, patients can be extended to Q20 using an extension method such as T&E

The frequency of monitoring visits should be based on the patient’s status and at the physician’s discretion.

Dosing diagram for illustrative purpose only.

*Following 3 monthly loading doses, intervals can be extended to Q16, dependent on visual and/or anatomic outcomes, and subsequently to Q20 (e.g. with a T&E regimen) if visual and/or anatomic outcomes are stable. Consult the SmPC for full posology.

The recommended dose is 8mg aflibercept, equivalent to 0.07 mL solution. The posology is the same for the nAMD and DME indications. The 8mg dose requires use of the EYLEA® 114.3 mg/ml vial.

EYLEA® at monthly doses of 8mg has not been studied for more than 3 consecutive doses.

Eylea® 8mg is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (nAMD) and visual impairment due to diabetic macular edema (DME).

    DME, diabetic macular edema. MoA, mechanism of action. nAMD, neovascular (wet) age-related macular degeneration. Q8, every 8 weeks. Q12, every 12 weeks. Q16, every 16 weeks. Q20, every 20 weeks. T&E, treat and extend. VEGF, vascular endothelial growth factor.

PP-EYL_8mg-IL-0020-1

    • 1
      EYLEA® 8mg SmPC as approved by the Israeli MoH.